Tucatinib-Based Triple Therapy Improves Survival in HER2+ Breast Cancer LM

A systemic regimen consisting of tucatinib (Tukysa), trastuzumab (Herceptin), and capecitabine has demonstrated a significant survival benefit for patients with HER2-positive breast cancer and leptomeningeal metastasis (LM), according to results from the phase 2 TBCRC049 trial (NCT03501979) published in Nature Cancer.¹ The study reported a median overall survival (OS) of 10 months, more than doubling the historical benchmark of 4.4 months for this high-risk population.

LM, the seeding of tumor cells into the leptomeninges and cerebrospinal fluid (CSF), remains one of the most devastating complications of advanced breast cancer. While newer therapies have extended survival for patients with parenchymal brain metastases, those with LM have historically been excluded from pivotal trials, leaving a critical gap in evidence-based treatment options.

Trial Design and Efficacy Outcomes

The nonrandomized, single-arm, multicenter study enrolled 17 female patients with HER2-positive metastatic breast cancer and newly diagnosed LM. At baseline, all patients had MRI evidence of LM, and 88% were symptomatic. The primary end point was OS, with secondary end points including central nervous system progression-free survival (CNS-PFS), objective response, and pharmacokinetics.

With a median follow-up of 18 months, the median OS reached 10 months (95% CI, 4.1-not reached). The median time to CNS progression was 6.9 months (95% CI, 2.3-13.8). Beyond survival, the triplet regimen achieved a composite LM objective response—incorporating neurological evaluation, neuroaxis imaging, and CSF cytopathology—in 38% of evaluable patients. Notably, the clinical benefit rate, defined as stable disease or better, was 100% among the 13 response-evaluable participants.

Pharmacokinetics and CSF Penetration

A key finding of TBCRC049 was the confirmation of tucatinib’s ability to penetrate the blood-CSF barrier. Tucatinib and its metabolite, ONT-993, were detectable in the CSF of all 13 patients for whom data were available after the initial dose. At steady state, tucatinib total CSF concentrations ranged from 0.94 ng/mL to 25 ng/mL. The median tucatinib total CSF-to-unbound plasma ratios ranged from 0.59 to 1.1, suggesting that the drug reaches therapeutic levels within the CNS compartment.

Neurological and Quality-of-Life Impact

Unlike many LM-directed therapies where the primary goal is merely to delay deterioration, the tucatinib-based regimen led to symptomatic improvement. Neurological target deficits improved in 58% of evaluable patients, with most improvements noted by the first restaging assessment.

Patient-reported outcomes also reflected clinical benefit. Using the Linear Analogue Scale Assessment (LASA), the mean improvement in quality-of-life scores over the course of the study was 13.5 points. Similarly, symptom burden, measured via the MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) module, showed a mean improvement of 32 points.

Safety Profile

The safety of the tucatinib-trastuzumab-capecitabine triplet was consistent with previously reported data in metastatic settings, such as the HER2CLIMB trial (NCT02614794).² Most treatment-emergent adverse events (TEAEs) were grade 1 or 2, including diarrhea, nausea, vomiting, and hand-foot syndrome. Grade 3 events included liver function test elevations (n = 3), nausea/vomiting (n = 1), and hand-foot syndrome (n = 1). One patient experienced a grade 4 elevation in alanine aminotransferase, which led to discontinuation but resolved within 1 month. Significantly, no treatment-emergent neurotoxicities were observed during the study.¹

Clinical Implications

The authors noted that while the study was limited by its small sample size and single-arm design, the results provide a much-needed prospective evidence base for systemic therapy in LM. The findings suggest that tucatinib-based systemic therapy is a feasible and effective alternative to more invasive approaches, such as intrathecal chemotherapy, which often lacks standardized response criteria and consistent quality-of-life benefits.

REFERENCES

1. Murthy RK, O’Brien M, Berry DA, et al. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results. Nat Cancer. Published online March 18, 2026. doi:10.1038/s43018-026-01120-7

2. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Erratum in: Ann Oncol. 2023 Jul;34(7):630. doi: 10.1016/j.annonc.2022.12.005. PMID: 34954044.